Shilpa Medicare Limited receives import alert for Unit 4, Jadcherla, Telangana facility

Shilpa Medicare Limited has received an Import Alert 66-40 on February 17, 2021, pursuant to the USFDA inspection of the Unit 4, Jadcherla, Telangana facility from Feb 13 - 20 and Feb 24-25, 2020.

Three products have been exempted from the Import Alert - Azacitidine for Injection, Cyclophosphamide Capsules and Erlotinib Tablets.

The company is committed to address the concerns raised by the USFDA and will work with the US FDA to resolve these issues at the earliest. The company upholds quality and compliance with utmost importance and are committed to maintaining cGMP and quality standards across all Shilpa facilities.

Shares of SHILPA MEDICARE LTD. was last trading in BSE at Rs.425.1 as compared to the previous close of Rs. 423.25. The total number of shares traded during the day was 5691 in over 315 trades.

The stock hit an intraday high of Rs. 429.1 and intraday low of 419. The net turnover during the day was Rs. 2414702.

Source : Equity Bulls

Keywords